138 related articles for article (PubMed ID: 9457836)
21. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy.
Bice WS; Prestidge BR; Grimm PD; Friedland JL; Feygelman V; Roach M; Prete JJ; Dubois DF; Blasko JC
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):921-7. PubMed ID: 9652858
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
23. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
24. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma.
Dattoli M; Wallner K; Sorace R; Koval J; Cash J; Acosta R; Brown C; Etheridge J; Binder M; Brunelle R; Kirwan N; Sanchez S; Stein D; Wasserman S
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):875-9. PubMed ID: 8751395
[TBL] [Abstract][Full Text] [Related]
25. Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy.
Prete JJ; Prestidge BR; Bice WS; Dubois DF; Hotchkiss LA
Radiat Oncol Investig; 1998; 6(2):90-6. PubMed ID: 9572685
[TBL] [Abstract][Full Text] [Related]
26. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
27. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society.
Viswanathan AN; Erickson BA
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):104-9. PubMed ID: 19619956
[TBL] [Abstract][Full Text] [Related]
28. Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy.
Chen CT; Waterman FM; Valicenti RK; Gomella LG; Strup SE; Dicker AP
Int J Cancer; 2001; 96 Suppl():83-8. PubMed ID: 11992390
[TBL] [Abstract][Full Text] [Related]
29. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract][Full Text] [Related]
30. Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy.
Schwartz DJ; Davis BJ; Vetter RJ; Pisansky TM; Herman MG; Wilson TM; LaJoie WN; Oberg AL
Brachytherapy; 2003; 2(2):98-102. PubMed ID: 15062147
[TBL] [Abstract][Full Text] [Related]
31. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
32. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
[TBL] [Abstract][Full Text] [Related]
33. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary?
Davis BJ; Haddock MG; Wilson TM; Rothenberg HJ; Bostwick DG; Herman MG; Pisansky TM
Tech Urol; 2000 Jun; 6(2):70-7. PubMed ID: 10798803
[TBL] [Abstract][Full Text] [Related]
34. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
35. A comparison of permanent prostate brachytherapy techniques: preplan vs. hybrid interactive planning with postimplant analysis.
Shanahan TG; Nanavati PJ; Mueller PW; Maxey RB
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):490-6. PubMed ID: 12023154
[TBL] [Abstract][Full Text] [Related]
36. Erectile function after permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
[TBL] [Abstract][Full Text] [Related]
37. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
38. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
[TBL] [Abstract][Full Text] [Related]
39. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698
[TBL] [Abstract][Full Text] [Related]
40. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
